9093: Prescribing Controlled Drugs - Best Practices to Reduce Risk (TN Physicians)
This course has been available since January of 2022. Policyholders who have already completed this course are not eligible to complete it again for premium credit or CME. Premium credit will not be given for completing the same course twice. If you are unsure whether you have already completed this course, click here to submit an inquiry or sign in and click the "My Activities" tab to see your recently completed activities.
This course discusses risks of prescribing controlled substances, including opioids for the treatment of pain and stimulants for the treatment of behavioral health conditions. The appropriate assessment and treatment of these conditions has a far-reaching impact on patient morbidity, mortality, and quality of life. The speakers provide an overview of current topics including addiction, pain states, mechanisms of pain, and behavioral health conditions. The course provides education on the Tennessee Chronic Pain Guidelines, specific action steps to assist in evaluation and diagnosis, as well as approaches to manage patients treated with controlled substances. Targeted Pain Treatment, screening tools, and medication management are explored.
- Identify risks of prescribing controlled substances including opioids for pain and stimulants for behavioral health conditions
- Develop risk management strategies to safely prescribe controlled substances for various conditions
- Utilize the targeted pain treatment model to accurately diagnose the cause(s) of pain and target the treatment(s) to the cause(s)
This course is an online video option. It consists of video modules, and each module is followed by a test.
- 2.0 hours of mandatory controlled substances CME credit for physicians and other prescribers (excluding Oklahoma DOs)
- 10% Premium Credit for Physician Policyholders
- Certificate of Participation for Non-Physicians
This CME course qualifies for 2.0 mandatory prescribing credit hours with all professional boards with the exception of the Oklahoma Board of Osteopathic Examiners. For information regarding your CME/CE requirements/credits, please contact your licensure board.
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Tennessee College of Medicine (UTCOM) and State Volunteer Mutual Insurance Company. The UTCOM is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation: The UTCOM designates this enduring material for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP: The AAFP has reviewed Prescribing Controlled Drugs: Best Practices to Reduce Risk and deemed it acceptable for up to 2.00 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 01/01/2023 to 12/31/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AOA: This program is eligible for two (2) credit hours in Category 2 of the Continuing Medical Education Program of the American Osteopathic Association. Physicians will need to submit a letter of completion from the University of Tennessee directly to the AOA to receive CME credits, or AOA members may self-report the activity.
Continuing Education for Non-Physicians: The UTCOM will issue Certificates of Participation to non-physicians for participating in this activity and designates it for CEUs using the national standard that 1 hour of educational instruction is awarded .1 CEU.
This activity was reviewed on January 26, 2022. This activity was released on January 1, 2022 and will expire on December 31, 2023. SVMIC will not process any completions after December 31, 2023.
No commercial support was received for this activity. No speakers plan to discuss off-label use. No planners or speakers have relevant financial relationships to disclose.
Michael Baron, MD, MPH
Dr. Michael Baron obtained an MD and MPH degree at Tulane University. He completed his anesthesiology residency at Washington University in St. Louis and his psychiatry residency at Vanderbilt University. He has maintained board certifications in anesthesiology, psychiatry, and addiction medicine. He has practiced in the Nashville area since 1998 in a variety of settings. He is a Clinical Assistant Professor at Vanderbilt University. His specialty is chronic pain and addiction. In 2006, he published original research showing that high-dose opioids increased chronic pain scores.
Dr. Baron was appointed to the Tennessee Board of Medical Examiners (BME) in 2010 and reappointed in 2015. He served as Chair of the Tennessee Controlled Substance Monitoring Database committee for three years. He helped write many different Tennessee Department of Health rules pertaining to the treatment of pain, prescribing controlled substances, and addiction. Dr. Baron resigned from the appointed positions in January 2017 to accept the Medical Director position of the Tennessee Medical Foundation – Physician Health Program. Dr. Baron serves on the steering committee for the Tennessee Chronic Pain Guidelines. He helped write the Federation of State Medical Boards policy on Professional Sexual Misconduct in 2019 and the Impaired Physician Policy in 2020. Dr. Baron is also the volunteer Medical Director for the Nashville/Davidson County Drug Court (DC4).
Craig Clark, MD
Child, Adolescent and Adult Psychiatrist & Chief Medical Officer, Nashville Neuro Psychiatric Associates (NNPA)
Craig Clark is a child, adolescent, and adult psychiatrist with nearly 30 years of experience as a clinician. He first attended West Virginia University as a Moore Chemistry Scholar and later Marshall University, from which he ultimately graduated college and medical school Magna Cum Laude.
Drawn to Vanderbilt by the prospect of working with the famed neuropsychiatrist David Bear, MD, Dr. Clark relocated to Nashville in 1988. There he completed his post-doctoral training, inclusive of a rotating internship, followed by a residency in adult psychiatry and a fellowship in child and adolescent psychiatry.
Throughout his career, Dr. Clark has served in many capacities, including Chief Fellow in Child Psychiatry, supervised Vanderbilt Child Fellowship Trainees, Medical Director for all child and adolescent inpatient and outpatient services at Centennial Medical Center’s Parthenon Pavilion, and Public Affairs Representative to the Tennessee Psychiatric Association.
He has traveled the country speaking to audiences of primarily fellow physicians on numerous topics in child, adolescent, and adult psychiatry both in industry-sponsored meetings and CME settings.
Before founding Nashville Neuro Psychiatric Associates (NNPA), Dr. Clark was in private practice at Associated Psychiatrists in Nashville.
Stephanie G. Vanterpool, MD, MBA, FASA
Dr. Stephanie Vanterpool is Assistant Professor of Anesthesiology and Director of Comprehensive Pain Services at the University of Tennessee Medical Center in Knoxville, TN. She earned her medical degree from Duke University School of Medicine, completing an anesthesiology residency at the University of North Carolina and a pain medicine fellowship at Wake Forest University Carolinas Pain Institute. She then returned to Duke to complete her Masters in Business Administration with a certificate in Health Sector Management at the Fuqua School of Business.
Her clinical and academic focus is on Targeted Pain Treatment – the accurate diagnosis and targeted treatment of pain using a multi-modal approach. With over a decade of pain and neuromodulation practice in both private practice and academic settings, Dr. Vanterpool avidly promotes use of Targeted Pain Treatment to help patients with chronic pain reduce opioid use and reclaim relief and functional quality of life. She is the founding course director for the annual Targeted Pain Treatment (TPT) Conference in Knoxville TN, geared towards primary care and specialist clinicians to help them "Treat the Source not the Score" and "Focus on Function" while helping their patients who live with chronic pain. Dr. Vanterpool also hosts quarterly Targeted Pain Treatment patient education events to inform patients of their treatment options and how they can live life not limited by pain.
In addition to her clinical duties, Dr. Vanterpool is also heavily involved in state and national advocacy initiatives. She is the immediate past President of the Tennessee Pain Society, serves on the Board of Directors for the North American Neuromodulation Society (NANS), is the Co-Chair of the NANS Diversity and Outreach Committee (DOC), and is the treasurer for the NANS Women in Neuromodulation (WIN).
For more information on Targeted Pain Treatment and Dr. Vanterpool's educational and advocacy efforts, please visit www.TPT-Toolkit.com.
- 2.00 AMA CME
- 2.00 Attendance